Subjective well-being (SWB)-as measured by survey questions on life satisfaction, positive affect, or happiness-is a major topic of research within psychology, economics, and epidemiology. Twin studies have found that SWB is genetically correlated with depression (characterized by negative affect, anxiety, low energy, bodily aches and pains, pessimism, and other symptoms) and neuroticism (a personality trait characterized by easily experiencing negative emotions such as anxiety and fear) [1] [2] [3] . Depression and neuroticism have received much more attention than SWB in genetic-association studies, but the discovery of associated genetic variants with either of them has proven elusive 4, 5 .
In this paper, we report a series of separate and joint analyses of SWB, depressive symptoms (DS), and neuroticism. Our primary analysis is a genome-wide association study (GWAS) of SWB based on data from 59 cohorts (N = 298,420). This GWAS identifies three loci associated with SWB at genome-wide significance (p < 5×10 -8 ). We supplement this primary analysis with auxiliary GWAS meta-analyses of DS (N = 180,866) and neuroticism (N = 170,910), performed by combining publicly available summary statistics from published studies with new genome-wide analyses of additional data. In these auxiliary analyses we identify two loci associated with DS and eleven with neuroticism, including two inversion polymorphisms. In depression data from an independent sample (N = 368,890), both DS associations replicate (p = 0.004 and p = 0.015).
In our two joint analyses, we exploit the high genetic correlation between SWB, DS, and neuroticism (i) to evaluate the credibility of the 16 genome-wide significant associations across the three phenotypes, and (ii) to identify novel associations (beyond those identified by the GWAS). For (i), we investigate whether our three SWB-associated SNPs "quasi-replicate" by testing them for association with DS and neuroticism. We similarly examine the quasi-replication record of the DS and neuroticism loci by testing them for association with SWB. We find that the quasi-replication record closely matches what would be expected given our statistical power if none of the genome-wide significant associations were chance findings. These results strengthen the credibility of (most of) the original associations. For (ii), we use a "proxy phenotype" approach 6 : we treat the set of loci associated with SWB at p < 10 -4 as candidates, and we test them for association with DS and neuroticism. At the Bonferroni-adjusted 0.05 significance threshold, we identify two loci associated with both DS and neuroticism and another two associated with neuroticism.
In designing our study, we faced a tradeoff between analyzing a smaller sample with a homogeneous phenotype measure versus attaining a larger sample by jointly analyzing data from multiple cohorts with Supplementary Tables 8-12 for details on cohorts, phenotype measures, genotyping, association models, and quality-control filters). For DS (N = 180,866), we meta-analyzed publicly available results from a study performed by the Psychiatric Genomics Consortium (PGC) 12 together with new results from analyses of the initial release of the UK Biobank data (UKB) 13 and the Resource for Genetic Epidemiology Research on Aging (GERA) Cohort 14 . In UKB (N = 105,739), we constructed a continuous phenotype measure by combining responses to two questions, which ask about the frequency with which the respondent experienced feelings of unenthusiasm/disinterest or unenthusiasm/disinterest in the past two weeks. The other cohorts had ascertained case-control data on major depressive disorder (GERA: Ncases = 7,231, Ncontrols = 49,316; PGC: Ncases = 9,240, Ncontrols = 9,519).
For neuroticism (N = 170,910), we pooled summary statistics from a published study by the Genetics of Personality Consortium (GPC) 4 with results from a new analysis of UKB data. The GPC (N = 63,661) harmonized different neuroticism batteries. In UKB (N = 107,245), our measure was the respondent's score on a 12-item version of the Eysenck Personality Inventory Neuroticism scale 15 .
In both the DS and neuroticism GWAS, the heterogeneous phenotypic measures are highly genetically correlated (Supplementary Table 1 ). As in our SWB analyses, there is substantial inflation of the median test statistics (λGC = 1.168 for DS, λGC = 1.317 for neuroticism), but the estimated LD Score intercepts (1.008 and 0.998, respectively) suggest that bias accounts for little or none of the inflation.
For DS, we identified two lead SNPs, indicated in the Manhattan plot (Fig. 1b) . For neuroticism, our metaanalysis yielded 16 loci that are independent according to our locus definition (Fig. 1c) . However, 6 of these reside within a well-known inversion polymorphism on chromosome 8 16 . We established that all genomewide significant signals in the inversion region are attributable to the inversion, and we confirmed that the inversion is associated with neuroticism in both of our neuroticism datasets, the GPC and the UKB (Online Methods and Supplementary Note). In our list of lead SNPs (Table 1) , we only retain the most strongly associated SNP from these 6 loci to tag the chromosome 8 inversion.
Another lead SNP associated with neuroticism, rs193236081, is located within a well-known inversion polymorphism on chromosome 17. We established that this association is attributable to the inversion polymorphism (Online Methods and Supplementary Note). Because this inversion yields only one significant locus and is genetically complex 17 , we hereafter simply use its lead SNP as its proxy. Our neuroticism GWAS therefore identified 11 lead SNPs, two of which tag inversion polymorphisms. A concurrent, unpublished neuroticism GWAS using a subset of our sample reports similar findings 18 .
As shown in Table 1 , the estimated effects of all lead SNPs associated with DS and neuroticism are in the range 0.020 to 0.031 SDs per allele (R 2 0.02% to 0.04%). In the UKB cohort we estimated the effect of an additional allele of the chromosome 8 inversion polymorphism itself on neuroticism to be 0.035 SDs (Supplementary Table 13 ).
Genetic overlap across SWB, DS, and neuroticism

Figure 2a
shows that the three pairwise genetic correlations between our phenotypes, estimated using bivariate LD Score regression 10 , are substantial: -0.81 (SE = 0.046) between SWB and DS, -0.75 (SE = 0.034) between SWB and neuroticism, and 0.75 (SE = 0.027) between DS and neuroticism. Using height as a negative control, we also examined pairwise genetic correlations between each of our phenotypes and height and, as expected, found all three to be modest, e.g., 0.07 with SWB (Supplementary Table 1 ). The high genetic correlations between SWB, DS, and neuroticism may suggest that the genetic influences on these phenotypes are predominantly related to processes common across the phenotypes, such as mood, rather than being phenotype-specific.
Quasi-replication and Bayesian credibility analyses
We assessed the credibility of our findings using a standard Bayesian framework 19, 20 in which a positive fraction of SNPs have null effects and a positive fraction have non-null effects (Online Methods). For each phenotype, the non-null effect sizes are assumed to be drawn from a normal distribution whose variance is estimated from the GWAS summary statistics. As a first analysis, for each lead SNP's association with its phenotype, we calculated the posterior probability of null association after having observed the GWAS results. We found that, for any assumption about the fraction of non-null SNPs in the range 1% to 99%, the probability of true association always exceeds 95% for all 16 loci (and always exceeds 98% for 14 of them).
To further probe the credibility of the findings, we performed "quasi-replication" exercises (Online Methods) in which we tested the SWB lead-SNPs for association with DS and neuroticism. We similarly tested the DS lead-SNPs and the neuroticism lead-SNPs for association with SWB. Below, we refer to the phenotype for which the lead SNP was identified as the first-stage phenotype and the phenotype used for the quasi-replication as the second-stage phenotype. To avoid sample overlap, for each quasi-replication analysis we omitted any cohorts that contributed to the GWAS of the first-stage phenotype.
Results of the quasi-replication of the three SWB lead-SNPs are shown in Figure 3a . For ease of interpretation, the reference allele for each association in the figure is chosen such that the predicted sign of the second-stage estimate is positive. We find that two out of the three SWB lead-SNPs are significantly associated with DS (p = 0.004 and p = 0.001) in the predicted direction. For neuroticism, where the secondstage sample size (N = 68,201) is about half as large, the SWB-increasing allele has the predicted sign for all three SNPs, but none reach significance.
Figures 3b and 3c
show the results for the DS and neuroticism lead-SNPs, respectively. In each panel, the blue crosses depict results from the quasi-replications where SWB is the second-stage phenotype. We find that the two DS lead-SNPs have the predicted sign for SWB, and one is nominally significant (p = 0.04). Finally, of the eleven neuroticism lead-SNPs, nine have the predicted sign for SWB. Four of the eleven are nominally significantly associated with SWB, all with the predicted sign. One of the four is the SNP tagging the inversion on chromosome 8 16 . That SNP's association with neuroticism (and likely with SWB) is driven by its correlation with the inversion (Supplementary Fig. 1) .
To evaluate what these quasi-replication results imply about the credibility of the 16 GWAS associations, we compared the observed quasi-replication record to the quasi-replication record expected given our statistical power. We calculated statistical power using our Bayesian framework, under the hypothesis that each lead SNP has a non-null effect on both the first-and second-stage phenotypes. Our calculations take into account both the imperfect genetic correlation between the first-and second-stage phenotypes and inflation of the first-stage estimates due to the well-known problem of winner's curse (Online Methods). Of the 19 quasi-replication tests, our calculations imply that 16.7 would be expected to yield the anticipated sign and 6.9 would be significant at the 5% level. The observed numbers are 16 and 7. Our quasi-replication results are thus consistent with the hypothesis that none of the 16 genome-wide significant associations are chance findings, and in fact strengthen the credibility of our GWAS results (Supplementary Table 14) .
Lookup of DS and neuroticism lead-SNPs
Investigators of an ongoing large-scale GWAS of major depressive disorder (N = 368,890) in the 23andMe cohort shared association results for the loci identified in our DS and neuroticism analyses (Online Methods and Supplementary Table 15) 21 . Because the depression sample overlaps with our SWB sample, we did not request a lookup of the SWB-associated SNPs.
In Figures 3b and 3c , the results are depicted as green crosses. For interpretational ease, we chose the reference allele so that positive coefficients imply that the estimated effect is in the predicted direction. All 13 associations have the predicted sign. Of the 11 neuroticism polymorphisms, four are significantly associated with depression at the 5% level. Both of the DS lead-SNPs replicate (p = 0.004 and p = 0.015), with effect sizes (0.007 and -0.006 SDs per allele) strikingly close to those predicted by our Bayesian framework (0.008 and -0.006) (Supplementary Table 14 and Supplementary Table 15 ). Table 1 summarizes the results for the 16 lead SNPs identified across our separate GWA analyses of the three phenotypes. The right-most column summarizes the statistical significance of the quasireplication and depression lookup analyses of each SNP.
Panel A of
Proxy-phenotype analyses
To identify additional SNPs associated with DS, we conducted a two-stage "proxy phenotype" analysis (Online Methods). In the first stage, we ran a new GWAS of SWB to identify a set of candidate SNPs. Specifically, from each locus exhibiting suggestive evidence of association (p < 10 -4 ) with SWB, we retained the SNP with the lowest p-value as a candidate. In the second stage, we tested these candidates for association with DS at the 5% significance threshold, Bonferroni-adjusted for the number of candidates. We used an analogous two-stage procedure to identify additional SNPs associated with neuroticism. The first-stage SWB sample differs across the two proxy-phenotype analyses (and from the primary SWB GWAS sample) because we assigned cohorts across the first and second stages so as to maximize statistical power for the overall procedure.
For DS, there are 163 candidate SNPs. 115 of them (71%) have the predicted direction of effect on DS, 20 are significantly associated at the 5% significance level (19 in the predicted direction), and two remain significant after Bonferroni adjustment. For neuroticism, there are 170 candidate SNPs. 129 of them (76%) have the predicted direction of effect, all 28 SNPs significant at the 5% level have the predicted sign, and four of these remain significant after Bonferroni adjustment ( Supplementary Fig. 2 and Supplementary   Tables 16 and 17) . Two of the four are the SNPs identified in the proxy-phenotype analysis for DS. Table 1 lists the four SNPs in total identified by the proxy-phenotype analyses.
Biological analyses
To shed some light on possible biological mechanisms underlying our findings, we conducted several analyses.
We began by using bivariate LD Score regression 10 to quantify the amount of genetic overlap between each of our three phenotypes and ten neuropsychiatric and physical health. Figures 2b and c display the estimates for SWB and the negative of the estimates for DS and neuroticism (since SWB is negatively genetically correlated with DS and neuroticism). SWB, DS, and neuroticism have strikingly similar patterns of pairwise genetic correlation with the other phenotypes. Figure 2b shows the results for the five neuropsychiatric phenotypes we examined: Alzheimer's disease, anxiety disorders, autism spectrum disorder, bipolar disorder, and schizophrenia. For four of these phenotypes, genetic correlations with depression (but not neuroticism or SWB) were reported in BulikSullivan et al. 10 . For schizophrenia and bipolar disorder, our estimated correlations with DS, 0.33 and 0.26, are substantially lower than Bulik-Sullivan et al.'s point estimates but contained within their 95% confidence intervals. By far the largest genetic correlations we estimate are with anxiety disorders: −0.73 with SWB, 0.88 with DS, and 0.86 with neuroticism. Genetic correlations estimated from GWAS data have not been previously reported for anxiety disorders.
Figure 2c
shows the results for five physical health phenotypes that are known or believed to be risk factors for various adverse health outcomes: body mass index (BMI), ever-smoker status, coronary artery disease, fasting glucose, and triglycerides. The estimated genetic correlations are all small in magnitude, consistent with earlier work, although the greater precision of our estimates allows us to reject null effects in most cases. The signs are generally consistent with those of the phenotypic correlations reported in earlier work between our phenotypes and outcomes such as obesity 22 , smoking 23, 24 , and cardiovascular health We found significant enrichment of CENTRAL NERVOUS SYSTEM for all three phenotypes and, perhaps more surprisingly, enrichment of ADRENAL/PANCREAS for SWB and DS. The cause of the ADRENAL/PANCREAS enrichment is unclear, but we note that the adrenal glands produce several hormones, including cortisol, epinephrine, and norepinephrine, known to play important roles in the bodily regulation of mood and stress.
It has been robustly found that blood serum levels of cortisol in patients afflicted by depression are elevated relative to controls 28 .
While the above analyses utilize the genome-wide data, we also conducted three analyses (Online Methods) restricted to the 16 GWAS and four proxy-phenotype SNPs in Table 1 . In brief, we ascertained whether each SNP (or a variant in strong linkage disequilibrium (LD) with it) falls into any of the following three classes: (i) resides in a locus for which genome-wide significant associations with other phenotypes have been reported (Supplementary Table 22 Table 23) , and (iii) is an eQTL in blood or in one of 14 other tissues (although the non-blood analyses are based on smaller samples) (Supplementary Table 24 ). Here we highlight a few particularly interesting results.
), (ii) is nonsynonymous (Supplementary
We found that five of the 20 SNPs are in loci in which genome-wide significant associations have previously been reported. Two of these five are schizophrenia loci. Interestingly, one of them harbors the gene DRD2, which encodes the D2 subtype of the dopamine receptor, a target for antipsychotic drugs 29 that is also known to play a key role in neural reward pathways 30 . Motivated by these findings, as well as by the modest genetic correlations with schizophrenia reported in Figure 2b , we examined whether the SNPs identified in a recent study of schizophrenia 31 are enriched for association with neuroticism in our nonoverlapping UKB sample (N = 107,245). We conducted several tests and found strong evidence of such enrichment (Online Methods). For example, we found that the p-values of the schizophrenia SNPs tend to be much lower than the p-values of a randomly selected set of SNPs matched on allele frequency (p = 6.50×10 -
71
).
Perhaps the most notable pattern that emerges from our biological analyses is that the inversions on chromosomes 8 and 17 are implicated consistently across all analyses. The inversion-tagging SNP on chromosome 8 is in LD with SNPs that have previously been found to be associated with BMI Table 22 ). We also conducted eQTL analyses in blood for the inversion itself and found that it is a significant cis-eQTL for 7 genes (Supplementary Table 24 ). As shown in Figure 4b , all 7 genes are positioned in close proximity to the inversion breakpoints, suggesting that the molecular mechanism underlying the inversion's effect on neuroticism could involve the relocation of regulatory sequences. Two of the genes (MSRA, MTMR9) are known to be highly expressed in tissues and cell types that belong to the nervous system, and two (BLK, MFHAS1) in the immune system. In the tissuespecific analyses, we found that the SNP tagging the inversion is a significant eQTL for two genes, AF131215.9 (in tibial nerve and thyroid tissue analyses) and NEIL2 (tibial nerve tissue), both of which are also located near the inversion breakpoint.
The SNP tagging the chromosome 17 inversion is a significant cis-eQTL for five genes in blood and is an eQTL in all 14 other tissues (Supplementary Table 24 MAPT, which is also implicated in both the blood and the other tissue-specific analyses, encodes a protein important in the stabilization of microtubules in neurons. Associations have been previously reported between SNPs in MAPT (all of which are in strong LD with our inversion-tagging SNP) and neurodegenerative disorders, including Parkinson's disease 34 and progressive supranuclear palsy 35 , a rare disease whose symptoms include depression and apathy.
DISCUSSION
The discovery of genetic loci associated with SWB, depression, and neuroticism has proven elusive. Our study identified several credible associations for two main reasons. First, our analyses had greater statistical power than prior studies because ours were conducted in larger samples. Our GWAS findings-three loci associated with SWB, two with DS, and eleven with neuroticism-support the view that GWAS can successfully identify genetic associations with highly polygenic phenotypes in sufficiently large samples 5, 36 . A striking finding is that two of our identified associations are with inversion polymorphisms. Second, our proxy-phenotype analyses further boosted power by exploiting the strong genetic overlap between our three phenotypes. These analyses identified two additional loci associated with neuroticism and two with both DS and neuroticism. Through our quasi-replication tests, we also demonstrated how studying genetically overlapping phenotypes in concert can provide evidence on the credibility of GWAS findings. Our direct replication of the two genome-wide significant associations with DS in an independent depression sample provides further confirmation of those findings (Fig. 2b and Supplementary Table 15 ).
We were able to assemble much larger samples than prior work in part because we combined data across heterogeneous phenotype measures. Our results reinforce the conclusions from our theoretical analysis that doing so increased our statistical power, but our strategy also has drawbacks. One is that mixing different measures may make any discovered associations more difficult to interpret. For example, since our DS phenotype is coarse and composed of varied measures, it is not clear which depressive symptoms are responsible for the genetic associations we found. Research studying higher quality measures of the various facets of SWB, DS, and neuroticism is a critical next step. Our results can help facilitate such work because if the variants we identify are used as candidates, studies conducted in the smaller samples in which more fine-grained phenotype measures are available can be well powered.
Another limitation of mixing different measures is that doing so may reduce the heritability of the resulting phenotype, if the measures are influenced by different genetic factors. Indeed, our estimates of SNP-based heritability 10 for our three phenotypes are quite low: 0.040 (SE = 0.002) for SWB, 0.047 (SE = 0.004) for DS, and 0.091 (SE = 0.007) for neuroticism. We correspondingly find that polygenic scores constructed from all measured SNPs explain a low fraction of variance in independent samples: ~0.9% for SWB, ~0.5% for DS, and ~0.7% for neuroticism (Online Methods). The low heritabilities imply that even when polygenic scores can be estimated using much larger samples than ours, they are unlikely to attain enough predictive power to be clinically useful.
According to our Bayesian calculations, the true explanatory power (corrected for winner's curse) of the SNP with the largest posterior R 2 is 0.003% for SWB, 0.002% for DS, and 0.011% for neuroticism (Supplementary Table 14) . These effect sizes imply that in order to account for even a moderate share of the heritability, hundreds or (more likely) thousands of variants will be required. They also imply that our study's power to detect variants of these effect sizes was not high-for example, our statistical power to detect the lead SNP with largest posterior R 2 was only ~13%-which in turn means it is likely that there exist many variants with effect sizes comparable to our identified SNPs that evaded detection. These estimates suggest that many more loci will be found in studies with sample sizes realistically attainable in the near future.
Online Methods
This article is accompanied by a Supplementary Note with details on the genome-wide association analyses and follow-up analyses reported in the article.
Accession codes. Meta-analysis results can be downloaded from the SSGAC website (http://www.thessgac.org/#!data/kuzq8). For neuroticism and DS, meta-analysis results from the combined analyses are provided for all variants. For SWB, meta-analysis results for all variants are provided for the full sample excluding 23andMe, which is subject to special restrictions. For the full SWB meta-analysis, we provide results for 10,000 SNPs.
Clumping algorithm. To identify the 16 approximately independent ("lead") SNPs shown in Panel A of Table 1 , we used the following clumping algorithm. First, the SNP with the smallest p-value was identified in the meta-analysis results. This SNP was designated the lead SNP of clump 1. Second, we identified all SNPs whose LD with the lead SNP exceeds R 2 = 0.1 and assigned them to clump 1. To generate the second clump, we removed the SNPs in clump 1 and then followed the same steps: the remaining SNP with lowest p-value was designated the lead SNP of clump 2, and all remaining SNPs whose LD with the lead SNP exceeds R 2 = 0.1 were assigned to clump 2. The process is repeated to identify further lead SNPs and their corresponding clumps until no genome-wide significant SNPs remain. The clumps define "loci" of the genome that are associated with the phenotype. For several of our other analyses (described below), we use the same clumping algorithm, albeit with lower p-value thresholds than genome-wide significance, to identify a set of approximately independent variants.
GWAS of SWB.
Genome-wide association analyses were performed at the cohort level according to a prespecified analysis plan. Genotyping was performed using a range of common, commercially available genotyping arrays. The analysis plan instructed cohorts to upload results imputed using the HapMap2 CEU (r22.b36) reference sample 37 . We meta-analyzed summary association statistics from 59 contributing cohorts with a combined sample size of 298,420 individuals. Before meta-analysis, a uniform set of quality-control (QC) procedures were applied to the cohort-level summary statistics, including but not limited to the EasyQC 38 protocol. All analyses were restricted to European-ancestry individuals.
We performed a sample-size-weighted meta-analysis of the cohort-level summary statistics in Metal
39
. To adjust standard errors for non-independence, we inflated them using the square root of the estimated intercept from a LD Score regression Table   7 reports association results from the following four meta-analyses: the primary SWB analysis, the LS analysis, the PA analysis, and the post hoc SWB analysis. For each phenotype, we provide association results for the set of approximately independent SNPs that attained a p-value smaller than 10 -5
. We identify these SNP using our clumping algorithm, but with the p-value threshold set at 10 -5 instead of genome-wide significance.
GWAS of DS and neuroticism. Our auxiliary genome-wide association studies of DS and neuroticism were conducted in 1000G-imputed data, combining new genome-wide association analyses with publicly available summary statistics from previously published studies. We applied a similar QC protocol to that used in our primary SWB analysis. In the DS meta-analysis (N = 180,866), we weighted the UKB analysis Two of our lead SNPs on chromosome 18 (rs1557341 and rs12961969) reached genome-wide significance in unconditional analyses, and their pairwise linkage disequilibrium is below our cutoff of R 2 = 0.10. They therefore satisfy our definition of approximate independence. We found in additional robustness analyses that the evidence that that these SNPs reflect independent genetic signals is weaker than for the remaining SNPs identified in our main analysis (Supplementary Note).
Population stratification. To quantify the fraction of the observed inflation of the mean test statistic that is due to bias, we used LD Score regression 10 . The estimated LD Score regression intercepts were all close to 1, suggesting no appreciable inflation of the test statistics attributable to population stratification in any of our SWB, DS, or neuroticism meta-analyses (Supplementary Fig. 7 ). For all three phenotypes, our estimates suggest that less than 2% of the observed inflation of the mean test statistic was accounted for by bias.
In our primary GWAS of SWB, we also used two family-based analyses to test for and quantify stratification biases. These analyses used within-family (WF) estimates, the coefficients from regressing the difference in phenotype across siblings on the difference in siblings' genotype (and controls). These WF estimates are not biased by population stratification because siblings share their ancestry entirely, and therefore differences in siblings' genotypes cannot be due to the siblings being from different population groups. We meta-analyzed association statistics from WF analyses conducted in four cohorts.
In the first analysis, we estimated the fraction of SNPs for which the signs of the WF estimates were concordant with the signs of the estimates obtained from a GWAS identical to our primary SWB GWAS except with the four family cohorts excluded. For the 112,884 approximately independent SNPs considered, we found a sign concordance of 50.83%, which is significantly greater than 50% (p = 1.04 × 10 -8 ). Under the null hypothesis of no population stratification, the observed sign concordance matches the expected rate after winner's curse adjustment nearly perfectly, 50.83%.
The second analysis utilized the WF regression coefficient estimates (i.e., not only their signs) to estimate the amount of stratification bias. For each SNP , let denote the GWAS estimate, and let , denote the WF estimate. Under the assumption that the causal effect of each SNP is the same within families as in the population, we can decompose the estimates as:
where is the true underlying GWAS parameter for SNP , is the bias due to stratification (defined to be orthogonal to and ), and and are the sampling variances of the estimates with E E 0.
Since stratification biases are absent in WF analyses, the second equation does not have a bias term. Whenever 0, the GWAS estimate of is biased away from the population parameter . The proportion of variance in the GWAS coefficients accounted for by true genetic signals can be written as:
Var .
In Supplementary Note, we show that with estimates of and , (and their standard errors) from independent samples, it is possible to consistently estimate the above ratio. We found that with 95% confidence, between 72% and 100% of the signal in GWAS estimates is a result of true genetic effects on SWB rather than stratification.
Analyses of inversion polymorphisms. Two genome-wide significant SNPs for the neuroticism analysis are located within well-known inversion polymorphisms, on chromosomes 8 and 17. Using the genotypic data available for UKB participants, we called the inversion genotypes for UKB participants using a PCAmixture method. For both inversions, the method clearly distinguishes 3 clusters of genotypes, corresponding to inversion genotypes (Supplementary Fig. 8) . We validated the PCA-mixture procedure using existing methods designed to call inversion genotypes 40 (Supplementary Table 26 ).
For both inversions, we established that the inversion-tagging SNPs were always located in close proximity of the inversion region ( Fig. 3b and Supplementary Figs. 8-9 ). Supplementary Tables 27-28 list the twenty variants that most strongly correlate with the PCs that capture the inversion polymorphisms on chromosome 8 and 17, respectively. In additional analyses, we confirmed that the inversion is associated with neuroticism and SWB in independent cohorts (Supplementary Tables 29-30 and Supplementary Fig.   10 ).
Proxy-phenotype analyses. In these analyses, we used a two-stage approach that has been successfully applied in other contexts 6 . In the first stage, we conducted a meta-analysis of our first-stage "proxy phenotype" and used our clumping procedure to identify the set of approximately independent SNPs at the p-value threshold of 10 -4 . In the second stage, we tested SNPs identified in stage 1 (or high-LD proxies for them) for association with a second-stage phenotype in an independent (non-overlapping) sample. In our analyses, we used our primary phenotype of SWB as the proxy-phenotype. We conducted one analysis with DS as the second-stage phenotype, and one analysis with neuroticism as the second-stage phenotype. In the analyses, we omit cohorts from the first-stage or second-stage as needed to ensure that the samples in the two stages are non-overlapping. Supplementary Table 31 lists the cohort restrictions imposed. These cohort restrictions, as well as the p-value threshold of 10 -4 , were chosen before the data were analyzed on the basis of statistical power calculations.
To test for cross-phenotype enrichment, we used a non-parametric procedure that tests whether the lead SNPs are more strongly associated with the second-stage phenotype than randomly chosen sets of SNPs with a similar distribution of allele frequencies. We generated 1,000 matched SNPs for each of the Y lead/lead-proxy SNPs. We then ranked the Y×1000 + Y SNPs by p-value and conducted a Mann-Whitney test 41 of the null hypothesis that the p-value distribution of the Y lead/lead-proxy SNPs are drawn from the same distribution as the Y×1000 matched SNPs.
To test the individual lead SNPs for experiment-wide significance, we examined whether any of the lead SNPs (or their high-LD proxies) are significantly associated with the second-stage phenotype at the Bonferroni-adjusted significance level of 0.05/Y.
Genetic correlations.
We used bivariate LD Score regression 10 to quantify the amount of genetic heterogeneity among the phenotypic measures pooled in each of our three separate meta-analyses. For SWB, we estimated a pairwise correlation of 0.981 (SE = 0.065) between LS and PA, 0.897 (SE = 0.017) between "WB" (our measure that combines LS and PA) and LS, and 1.031 (SE = 0.019) between PA and WB. For DS, we estimated a genetic correlation of 0.588 (SE = 0.242) between GERA and PGC, 0.972 (SE = 0.216) between GERA and UKB, and 0.797 (SE = 0.108) between UKB and PGC. Finally, we estimated a genetic correlation of 1.11 (SE = 0.14) between the measures of neuroticism in the UKB analyses and the summary statistics from a previously published meta-analysis 4 .
Using the same method, we estimated the pairwise genetic correlations between our three phenotypes of SWB, DS, and neuroticism and between each of our three phenotypes and the ten neuropsychiatric and physical health variables (for which publicly available summary statistics were available).
Bayesian credibility analyses.
To evaluate the credibility of our findings, we use a standard Bayesian framework 19 in which our prior distribution for any SNP's effect is: ~ 0, with probability 0 o t h e r w i s e . .
Here, is the fraction of non-null SNPs, and is the variance of the non-null SNPs for trait j ∈ {SWB, DS, neuroticism}. In this framework, credibility is defined as the probability that a given SNP is non-null.
We begin with univariate analyses of the GWAS results that do not incorporate the additional information from the quasi-replication analyses of the 16 lead SNPs reported in Table 1 . We use the three SWBassociated SNPs to illustrate our approach, but we use analogous procedures when analyzing DS and neuroticism. We calculate credibility for each value ∈ 0.01,0.02, … ,0.99 . For each assumed value of , we estimate by maximum likelihood (Supplementary Note). For each SNP, we use Bayes' rule to obtain a posterior estimate of credibility for each of the assumed values of . Supplementary Figure 12 shows that for all considered values of and all three SNPs, the posterior probability that the SNP is null is below 1%. Similar analyses of the DS and neuroticism SNPs show that the posterior probability never exceeds 5%.
In our joint analyses, we consider two phenotypes with genetic correlation . We make the simplifying assumption that the set of null SNPs is the same for both phenotypes. The joint distribution of a SNP's effect on the two phenotypes is then given by ~ 0 0 , with probability 0 0 otherwise.
With coefficient estimates, and , obtained from non-overlapping samples, the variance-covariance matrix of the estimation error will be diagonal. We denote the diagonal entries of this matrix, which represent the variances of the estimation error in the two samples, by and . This gives us the joint prior distribution otherwise.
To select parameter values for the prior, we use the estimates of reported in Supplementary Table 1 , and we estimate the parameters , , and from GWAS summary statistics using a maximum likelihood procedure. For this procedure, we make the standard assumption 10, 42 that the variance of a SNP's effect size is inversely proportional to the variance of its genotype, 2 MAF 1 MAF . (This assumption implies that rare SNPs are more likely to have large effects.)
The credibility estimates follow from applying Bayes' Rule to calculate either the probability that the SNP is non-null (an event denoted ) given only the first-stage estimate, | , or the probability that the SNP is non-null conditional on the results of both the first-stage GWAS and the quasi-replication analysis, | , . Credibility estimates for our lead SNPs are in Supplementary Table 14 .
To calculate the expected record of a replication or quasi-replication study, we assume that the SNP is nonnull for both phenotypes. (This is analogous to a standard power calculation for a single phenotype, in which the SNP is assumed to be non-null.) Under this assumption, and are jointly normally distributed, implying that the conditional distribution of given is
Using this equation, we can calculate the probability that the GWAS estimates will have concordant signs across the two phenotypes, or that the GWAS estimate of the second-stage phenotype will reach some level of significance (or other measures of replicability). These probabilities can be summed over the set of lead SNPs to generate the expected number of SNPs meeting the criterion.
To obtain effect-size estimates for a SNP that are adjusted for the winner's curse (Supplementary Table   32 ), we use the mean of the posterior distribution of the SNP's effect, conditional on the quasi-replication result and the SNP being non-null. The posterior distribution is Lookup of DS and neuroticism-associated SNPs in an independent depression study. We partnered with the investigators of an ongoing large-scale GWAS of major depressive symptoms (N = 368,890) to follow up on the associations identified in the DS and neuroticism analyses (and reciprocally supplied them with association results for their most significant associations). The participants of the study were all Europeanancestry customers of 23andMe, a personal genomics company, who responded to online survey questions about mental health. We did not request results for the SNPs identified in the SWB or proxy-phenotype analyses, since these were both conducted in samples that overlap with 23andMe's depression sample. For details on association models, quality-control filters, and the ascertainment of depression status, we refer to the companion study 21 . The p-values we report are based on standard errors that have been inflated by the square by the intercept from an LD score regression 10 .
Polygenic prediction. To evaluate the predictive power of a polygenic score derived from the SWB metaanalysis results, we used two independent hold-out cohorts: the Health and Retirement Study (HRS 43 ) and the Netherlands Twin Register (NTR 44, 45 ). To generate the weights for the polygenic score, we performed meta-analyses of the pooled SWB phenotype excluding each of the holdout cohorts, applying a minimum-sample-size filter of 100,000 individuals. Using the summary statistics from this meta-analysis, we constructed two sets of polygenic scores: (1) LDpred polygenic scores, with weights constructed from conditional SNP effects estimated from summary statistics using information about LD structure from a reference sample 20 , and (2) linear polygenic scores using the unconditional GWAS effect sizes 46 . We examined the predictive power of the score for the following outcomes: SWB, LS, PA, depression, the NEO Big Five personality traits 47 , and height (the last being included as a negative control). The results from these analyses are reported in Supplementary Table 32 and depicted in Supplementary Figure 13 .
Enrichment of schizophrenia SNPs for association with neuroticism. In post hoc analyses, we used the test of cross-phenotype enrichment described in the "Proxy-phenotype analysis" Online Methods section to examine whether the genome-wide associations that have been reported for schizophrenia showed evidence for enriched association with neuroticism in a non-overlapping sample. Among our phenotypes, we focused on neuroticism to maximize power. For the biological annotation of the 20 SNPs in Table 1 , we generated a list of LD partners for each of the original SNPs. A SNP was considered an LD partner for the original SNP if (i) its pairwise LD with the original SNP exceeded R 2 = 0.6 and (ii) it was located within 250kb of the original SNP. We also generated a list of genes residing within loci tagged by our lead SNPs (Supplementary Table 34) .
We used the NHGRI GWAS catalog 50 to determine which of our 20 SNPs (and their LD partners) were in LD with SNPs for which genome-wide significant associations have been previously reported. Since the GWAS catalog does not always include the most recent GWAS results available, we included additional recent GWAS studies. We used the tool HaploReg 51 to identify nonsynonymous variants in LD with any of the 20 SNPs or their LD partners.
We examined whether the 20 polymorphisms in Table 1 were associated with gene expression levels (Supplementary Table 24 ). The cis-eQTL associations were performed in 4,896 peripheral-blood gene expression and genome-wide SNP samples from two Dutch cohorts measured on the Affymetrix U219 platform 44, 45, 52 . We considered a SNP a potential cis-eQTL if the distance between the SNP and the midpoint of the probe set was smaller than 1Mb. The cis-eQTL analyses of the inversion were conducted separately. To supplement the analyses in blood, we performed eQTL lookups of our 20 SNPs in the Genotype-Tissue Expression Portal (www.GTExportal.org) 53, 54 . For a given SNP, the portal provides results in various tissues for tests of association between the SNP and gene expression of genes whose transcription start site is within one Mb of the SNP. We restricted the search to the following trait-relevant tissues: hippocampus, hypothalamus, anterior cingulate cortex (BA24), putamen (basal ganglia), frontal cortex (BA9), nucleus accumbens (basal ganglia), caudate (basal ganglia), cortex, cerebellar hemisphere, cerebellum, tibial nerve, thyroid, adrenal gland, and pituitary.
Finally, using a gene co-expression database 55 , we explored the predicted functions of genes co-locating with the 20 SNPs in Table 1 (Supplementary Table 35 Table 1 . Summary of polymorphisms identified across analyses. EA: effect allele. EAF: effect allele frequency. All effect sizes are reported in units of SDs per allele. "Quasi-Repl.": phenotypes for which SNP was found to be nominally associated in quasi-replication analyses conducted in independent samples. *significant at the 5%-level, **significant at the 1%-level, ***significant at the 0.1%-level. #inversion-tagging polymorphism on chromosome 8. ##inversion-tagging polymorphism on chromosome 17 
